Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: As a part of a wider project aimed to assess sex-related differences in adverse effects and efficacy of antiseizure medications (ASMs), we performed a systematic review focusing on differences in response to ASMs between males and females with epilepsy.

Method: We conducted a comprehensive literature search in the PubMed database. The search was conducted without restriction on publication date, and all results up to September 2022 were included. We included all the articles written in English, Italian, Spanish, or French language evaluating the response to ASMs in people with epilepsy (PWE), with specific mention of the two sexes. The Newcastle-Ottawa Scale and the Jadad Scale were used to assess study quality.

Results: A total of 1778 studies were identified. Of these, 60 studies searched for sex differences and among those, 46 (76%) did not identify statistically significant differences. Only 14 studies (23%) identified sex as a statistically significant variable in ASM efficacy. Among those, a greater number of studies reported higher rates of seizure reduction or seizure freedom in males using different ASMs, with 9 studies vs 5 in which drug response was higher in males.

Conclusions: Our study has identified male sex as a predictor of drug response in epilepsy in the majority of studies that found sex differences. However, the scarcity of data found in the literature highlights the need for a systematic evaluation of sex as a variable influencing the response to medications in clinical research.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-025-13250-6DOI Listing

Publication Analysis

Top Keywords

sex differences
12
antiseizure medications
8
people epilepsy
8
systematic review
8
response asms
8
drug response
8
sex
6
response
6
studies
6
differences
5

Similar Publications

Background: Migraine care is often suboptimal owing to undertreatment, variation in clinical outcomes and administration methods among existing treatments, and between- and within-individual heterogeneity in the clinical course of migraine. In response to these challenges, preference studies have been increasingly conducted to inform treatment decision-making and development. However, gaps remain in understanding how treatment preferences have been assessed across different migraine studies.

View Article and Find Full Text PDF

Purpose: Living donor kidney transplantation is a critical strategy to address the growing burden of end-stage kidney disease (ESKD) in Malaysia. Whilst living donation is generally safe, concerns remain regarding long-term donor outcomes. This study aimed to evaluate renal function and morbidity changes in living kidney donors 1 year post-donation, and to identify predictors of impaired kidney function.

View Article and Find Full Text PDF

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by complex disturbances in both innate and adaptive immune responses, often leading to multi-organ involvement. One of the key features of SLE pathogenesis is endothelial dysfunction, which contributes to immune cell infiltration and vascular inflammation. In this context, adhesion molecules such as platelet endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) may reflect the degree of endothelial activation.

View Article and Find Full Text PDF

Objectives: The escalating global incidence of obesity, cardiometabolic disease and sarcopenia necessitates reliable body composition measurement tools. MRI-based assessment is the gold standard, with utility in both clinical and drug trial settings. This study aims to validate a new automated volumetric MRI method by comparing with manual ground truth, prior volumetric measurements, and against a new method for semi-automated single-slice area measurements.

View Article and Find Full Text PDF

Background: Comorbidities may affect incidence and management of cancers. The burden of comorbidities among AIAN cancer patients and survivors is unknown.

Methods: Using SEER-Medicare, we identified AIAN people aged 66+ years diagnosed with female breast, lung, and colorectal cancers (2000-2019), with at least one year of Medicare coverage prior to diagnosis.

View Article and Find Full Text PDF